Literature DB >> 35502773

Limitations of randomized, controlled, double-blinded studies in determining safety and effectiveness of treatments.

W Clark Lambert1, Edmund J Janniger1.   

Abstract

Randomized, controlled, double-blinded studies, in which treated subjects are randomly selected from the same pool as controlled (untreated) ones and neither the caregiver nor the patient knows which is which, are widely accepted as the gold standard of experimental medicine. There are well-documented advantages of such studies. There are, however, significant limitations of them as well of which it is important to be aware. Notably, physicians who rely on experience and on what they were taught in medical school and post-graduate training are not necessarily wrong when this information runs contrary to the results of such studies. Some limitations of them are widely known and taught, such as inadequate sample size, failure of proper randomization, et cetera; others are less well-known. We shall focus on the latter.

Entities:  

Keywords:  COVID-19; clinical research; design of experiments; medical statistics; therapeutics

Mesh:

Year:  2022        PMID: 35502773     DOI: 10.1080/03007995.2022.2073121

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.705


  1 in total

1.  Reply to "Recommendation on an updated standardization of serum magnesium reference ranges," Jeroen H.F. de Baaij et al.

Authors:  Rhian M Touyz; Federica Wolf; Jeanette A Maier; Andrea Rosanoff; Christina West; Ronald J Elin; Oliver Micke; Shadi Baniasadi; Mario Barbagallo; Emily Campbell; Fu-Chou Cheng; Rebecca B Costello; Claudia Gamboa-Gomez; Fernando Guerrero-Romero; Nana Gletsu-Miller; Bodo von Ehrlich; Stefano Iotti; Ka Kahe; Dae Jung Kim; Klaus Kisters; Martin Kolisek; Anton Kraus; Magdalena Maj-Zurawska; Lucia Merolle; Mihai Nechifor; Guitti Pourdowlat; Michael Shechter; Yiqing Song; Yee Ping Teoh; Taylor C Wallace; Kuninobu Yokota
Journal:  Eur J Nutr       Date:  2022-10-07       Impact factor: 4.865

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.